Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party

Raynier Devillier,[1] Jean-Hugues Dalle,[2] Austin Kulasekararaj,[3] Maud D'aveni,[4] Laurence Clément,[4,5] Alicja Chybicka,[6] Stéphane Vigouroux,[5] Patrice Chevallier,[7] Mickey Koh,[8] Yves Bertrand,[9] Mauricette Michallet,[10] Marco Zecca,[11] Ibrahim Yakoub-Agha,[12] Jean-Yves Cahn,[13] Per Ljungman,[14] Marc Bernard,[15] Pascale Loiseau,[16,17] Valérie Dubois,[18] Sébastien Maury,[19] Gérard Socié,[20] Carlo Dufour,[21]* and Regis Peffault de Latour[20]*

[1]Hematology Department, Institut Paoli Calmettes, Marseille, France; [2]Pediatric Hematology Unit, Robert Debré University Hospital, Paris, France; [3]Hematology Department, King's College Hospital, London, UK; [4]Pediatric Hematology Unit, University Hospital, Nancy, France; [5]Hematology Department, Haut-Leveque Hospital and Bordeaux University Hospital, Pessac, France; [6]Hematology Department, Wroclaw Medical University, Poland; [7]Hematology Department, University Hospital, Nantes, France; [8]Hematology Department, St. George's Hospital, London, UK; [9]Pediatric Hematology Unit, University Hospital, Lyon, France; [10]Hematology Department, University Hospital, Lyon, France; [11]Hematology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; [12]Hematology Department, University Hospital, Lille, France; [13]Hematology Department, University Hospital, Grenoble, France; [14]Hematology Department, Karolinska University Hospital, Stockholm, Sweden; [15]Hematology Department, University Hospital, Rennes, France; [16]HLA Laboratory, Saint-Louis University Hospital, Paris, France; [17]French Society of Histocompatibility and Immunogenetics (SFHI), France; [18]HLA Laboratory, Etablissement Français du Sang, Lyon, France; [19]Hematology Department, Henri Mondor Hospital, Créteil, France; [20]BMT Department, Saint-Louis Hospital, Diderot Paris 7 University, Paris, France; and [21]Clinical and Experimental Haematology Unit, Giannina Gaslini Children's Hospital, Genova, Italy

**CD and RPdL contributed equally to this work.*

 doi:10.3324/haematol.2015.138727

Received: October 29, 2015.

Accepted: April 5, 2016.

Pre-published: April 7, 2016.

Correspondence: regis.peffaultdelatour@aphp.fr

Online Supplementary Appendix

SFGM-TC participating centers:

Hôpital Saint-Louis, Paris, Pr Gérard Socié; Hôpital Robert Debré, Paris, Pr Jean-Hugues Dalle; Hôpital d'enfants de Brabois, Nancy, Dr Laurence Clément; CHU Haut Lévêque, Pessac, Pr Noël Milpied; Institut d'hématologie et d'oncologie pédiatrique, Lyon, Pr Yves Bertrand; CHRU Hôtel-Dieu, Nantes, Dr Patrice Chevallier, Dr Fanny Rialland; CHRU Hôpital Claude Huriez, Lille, Pr Ibrahim Yakoub-Agha; Centre Hospitalier Lyon Sud, Pr Mauricette Michallet; CHU de Grenoble, Pr Jean-Yves Cahn; CHU de Rennes, Pr Thierry Lamy, Dr Virginie GANDEMER; Strasbourg Hôpital Hautepierre, Dr Bruno Lioure; Clermont-Ferrand , Pr Jacques Olivier Bay, Pr François Demeocq; Institut Paoli Calmettes, Marseille, Pr Didier Blaise ; Hôpital d'Enfants de La Timone, Marseille, Pr Gérard Michel; Hôpital St Eloi Montpellier, Dr Nathalie Fegueux; CHU de Poitiers, Dr Natacha Maillard; IUCT Oncopole, Toulouse, Dr Anne Huynh; CHU Côte de Nacre, Caen, Dr Oumedaly Reman; HIA Percy, Clamart, Dr Jean-Valère Malfuson; Hôpital Henri Mondor, Créteil, Pr Catherine Cordonnier; Hôpital Jeanne de Flandre, Lille, Dr Bénédicte Bruno; Hôpital Necker, Paris, Dr Felipe Suarez, Pr Alain Fisher; Institut Gustave Roussy, Villejuif, Pr Jean-Henri Bourhis; CHU d'Angers, Pr Norbert Ifrah; Hôpital Jean Minjoz, Besançon, Pr Eric Deconinck; Hôpitaux Groupe Pellegrin, Bordeaux, Dr Charlotte Jubert; Hôpital de l`ARCHET, Nice Pr Pierre-Simon Rohrlich; Groupe Hospitalier Pitié-Salpêtrière, Paris, Dr Stéphanie N'Guyen; Hôpital Saint-Antoine, Paris, Pr Mohamad Mohty; Centre Henri Becquerel, Rouen, Dr Nathalie Contentin; Hôpital Charles Nicolle, Rouen, Dr Aude Marie-Cardine

EBMT participating centers

Wroclaw Medical University, Wroclaw, Poland, Alicja Chybicka; St. George`s Hospital, London, United Kingdom, Mickey Koh; Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Marco Zecca; Karolinska University Hospital, Stockholm, Sweden, Per Ljungman; Silesian Medical Academy, Katowice, Poland, Slawomira Kyrcz-Krzemien; Azienda Ospedaliero Universitaria, Bologna, Italy, Andrea Pession; Institute G. Gaslini, Genova, Italy, Edoardo Lanino; Leiden University Hospital, Leiden, Netherlands, The, Joan Hendrik Veelken; University Hospital Gasthuisberg, Leuven, Belgium, Johan Maertens; Clinica di Oncoematologia Pediatrica, Padova, Italy, Chiara Messina; Bristol Royal Hospital for Children, Bristol, United Kingdom, Stephen Robinson; University Hospital Motol, Prague,

Czech Republic, Petr Sedlacek; Rigshospitalet, Bone Marrow Transplant Unit L 4043, Copenhagen, Denmark, Henrik Sengeloev; Ospedale San Martino, Genova, Italy, Andrea Bacigalupo; Hannover Medical School, Hannover, Germany, Arnold Ganser; Umea University Hospital, Umeå, Sweden, Anders Wahlin; University of Freiburg, Freiburg, Germany, Jürgen Finke; University Hospital, Basel, Switzerland, Jakob Passweg; Turku University , Turku, Finland, Maija Itälä-Remes; Ospedale S. Camillo-Forlanini, Rome, Italy, Ignazio Majolino; Inst. Português de Oncologia do Porto, Porto, Portugal, Antonio Campos; St. Anna Kinderspital, Vienna, Austria, Wolfgang Holter; Constantiaberg Medi-Clinic, Cape_Town, South Africa, Akin Abayomi; University Medical Center Mainz, Mainz, Germany, Matthias Theobald; University of Helsinki, Helsinki, Finland, Kim Vettenranta; University Medical Centre, Utrecht, Netherlands, The, Eefke Petersen; Great Ormond Street Hospital Children's Charity, London, United Kingdom, Paul Veys; Bone Marrow Transplant Unit Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom, Grant McQuaker; Hôpitaux Universitaires de Genève, Geneva, Switzerland, Yves Chalandon; Hospital Vall d`Hebron, Barcelona, Spain, José Sánchez de Toledo Codina; Klinikum Grosshadern, Munich, Germany, Johanna Tischer; Central Manchester NHS Trust, Department of Paediatric Haematology, Manchester, United Kingdom, R.F. Wynn; DCTK, Wroclaw, Poland, Andrzej Lange; St. István & St. Laszlo Hospital, Dept. Haematology and Stem Cell Transplant, Budapest, Hungary, Tamás Masszi; George Papanicolaou General Hospital, Thessaloniki, Greece, Achilles Anagnostopoulos; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, Alessandro Rambaldi; Federal Research Center for Pediatric Hematology, Moscow, Russia, Alexei Maschan; Charles University Hospital, Pilsen, Czech Republic, Pavel Jindra; Niño Jesus Children`s Hospital, Madrid, Spain, Miguel Angel Diaz; Hospital Universitario La Paz, Madrid, Spain, Ana Sastre; Universitaetsklinikum Dresden, Dresden, Germany, G. Ehninger; United St. Istvan and St. Laszlo Hospital, Budapest, Hungary, Gergely Kriván; Cliniques Universitaires St. Luc, Brussels, Belgium, Xavier Poiré; Nijmegen Medical Centre, Nijmegen, Netherlands, The, N. Schaap; Hospital U. Marqués de Valdecilla, Santander, Spain, Carlos Richard Espiga; Yorkshire Blood & Marrow Transplant Programme, Leeds, United Kingdom, Maria Gilleece; University Hospital, Essen, Germany, Dietrich Beelen; Hospital Santa Creu i Sant Pau, Barcelona, Spain, Jorge Sierra; Northern Centre for Bone Marrow Transplantation, Freeman Hospital, Adult HSCT unit, Newcastle-Upon-Tyne, United Kingdom, Matthew Collin; Centro Trapianti di Midollo Osseo, Monza, Italy, Andrea Biondi; Birmingham Heartlands Hospital, Birmingham, United Kingdom, Manos Nikolousis; Sahlgrenska

University Hospital, Goeteborg, Sweden, Mats Brune; Onco-Ematologia Pediatrica, Torino, Italy, Franca Fagioli; Deutsche Klinik für Diagnostik, Wiesbaden, Germany, Gernot Stuhler; Charité - Campus Benjamin Franklin, Berlin, Germany, Wolfgang Blau; Klinik für Knochenmarktransplantation, Idar-Oberstein, Germany, Axel A. Fauser; University Hospital Brno, Brno, Czech Republic, Jiri Mayer; Poznan University of Medical Sciences, Poznan, Poland, Jacek Wachowiak; Royal Hospital for Sick Children, Glasgow, United Kingdom, Brenda E. Gibson; Poznan University of Medical Sciences, Poznan, Poland, M. Komarnicki; ¨Tor Vergata¨ University of Rome, Rome, Italy, William Arcese; Our Lady`s Children`s Hospital, Dublin, Ireland, Owen Smith ; North Trent BMT Programme (Adults), Sheffield, United Kingdom, John Snowden; Sheffield Childrens NHS Foundation Trust, Sheffield, United Kingdom, Ajay Vora; Klinik fuer Innere Medzin III, Ulm, Germany, Donald Bunjes; Imperial College , London, United Kingdom, Jane Apperley; University Hospital, Zürich, Switzerland, Urs Schanz; Hospital Clinic, Barcelona, Spain, Montserrat Rovira; Universität Tübingen, Tübingen, Germany, L. Kanz; Rikshospitalet, Oslo, Norway, Tobias Gedde-Dahl; Hosp. Reina Sofia, Córdoba, Spain, Pedro Gomez García; Erasmus MC-Daniel den Hoed Cancer Centre, Rotterdam, Netherlands, The, Prof. J.J. Cornelissen; Ospedale Civile, Pescara, Italy, Paolo Di Bartolomeo; Cancer and Haematology Centre Churchill Hospital, Department of Haematology , Oxford, United Kingdom, Andy Peniket; University Hospital Schleswig-Holstein, Div. Stem Cell Transplantation and Immunotherapy, Kiel, Germany, Martin Gramatzki; Hospital Clínico Universitario, Valencia, Spain, Carlos Solano; University Hospital Center Rebro, Zagreb, Croatia, Damir Nemet; Ospedale di Careggi, Firenze, Italy, Alberto Bosi; University Hospital Graz, Graz, Austria, Hildegard Greinix; Univ. Est. de Campinas/TMO/UNICAMP, Campinas, Brazil, Carmino A. De Souza; Heinrich Heine Universität, Düsseldorf, Germany, Guido Kobbe; HUCH Comprehensive Cancer Center, Helsinki, Finland, Liisa Volin; University of Heidelberg, Heidelberg, Germany, Peter Dreger; Istituto per l`Infanzia `IRCCS Burlo Garofolo`, Trieste, Italy, Natalia Maximova; Pesaro Hospital, Pesaro, Italy, Guiseppe Visani; Universitätsklinikum Jena, Jena, Germany, Inken Hilgendorf; University of Cologne, Cologne, Germany, Michael Hallek; University Hospital, Tübingen, Germany, Rupert Handgretinger ; Azienda Ospedaliero Universitaria di Modena Policlinico, Modena, Italy, Franco Narni; University Medical Center Groningen (UMCG), Groningen, Netherlands, The, G.W. van Imhoff; University Hospital, Olomouc, Czech Republic, Edgar Faber; Hospital Vall d`Hebron, Barcelona, Spain, David Valcárcel; Borsod University Hospital, Miskolc, Hungary, Nagy Kalman; Manchester Royal Infirmary, Manchester,

United Kingdom, Eleni Tholouli; University Hospital, Bratislava, Slovakia, Martin Mistrik; University Hospital Eppendorf, Hamburg, Germany, Nicolaus Kröger; Akdeniz University Medical School, Antalya, Turkey, Alphan Kupesiz; Evangelismos Hospital, Athens, Greece, Dimitrios Karakasis; Universitair Ziekenhuis Brussel, Brussels, Belgium, Rik Schots; Pediatric University Teaching Hospital, Bratislava, Slovakia, Sabina Sufliarska; The Children`s Hospital at Westmead, Sydney, Australia, Peter J. Shaw; University of Liege, Liege, Belgium, Yves Beguin; Hospital Clínico, Salamanca, Spain, Dolores Caballero; Charles University Hospital, Hradec_Králové, Czech Republic, Pavel Zák; University Hospital, Linköping, Sweden, Anna Sandstedt; University of Jena, Jena, Germany, Bernd Gruhn; Chaim Sheba Medical Center, Tel-Hashomer, Israel, Arnon Nagler; University of Napoli, Napoli, Italy, Antonio Risitano; St. Bartholomew`s and The Royal London NHS Trust, London, United Kingdom, John Gribben; Unità Operativa Oncoematologia Pediatrica, Pisa, Italy, Claudio Favre; Charité Universitätsmedizin Berlin, Berlin, Germany, Renate Arnold; Central Clinical Hospital, Warsaw, Poland, Wieslaw Wiktor-Jedrzejczak.

Supplemental Table 1: Univariate analyses of confounding factors to select those used to adjust the multivariate analyses

	Univariate analysis		
	4-yr OS	**[95%CI]**	**p**
Transplantation period			
2000-05 (n = 46)	52%	[39-69]	0.018
2006-12 (n = 93)	74%	[66-84]	
Donor age			
< 35 years (n = 61)	68%	[55-83]	0.269
≥ 35 years (n = 65)	62%	[51-75]	
CMV serostatus			
D-/R- (n = 53)	71%	[59-87]	0.125
Other (n = 83)	61%	[53-73]	
Graft source			
BM (n = 118)	67%	[58-76]	0.573
PBSC (n = 21)	60%	[42-86]	
GVHD prophylaxis			
CSA + MTX (n = 95)	67%	[57-78]	0.558
Other (n = 45)	64%	[51-80]	
TBI-based conditioning			
No (n = 75)	66%	[56-78]	0.964
Yes (n = 64)	66%	[54-79]	
In vivo T-cell depletion			
No (n = 27)	55%	[39-68]	0.145
Yes (n = 112)	67%	[67-89]	

95%CI = 95% confidence interval; BM = bone marrow; CSA = cyclosporine A; D-/R- = seronegative donor and recipient; GVHD = graft versus host disease; MTX = methotrexate; OS = overall survival; PBSC = peripheral blood stem cell; TBI = total body irradiation

Supplemental Table 2: Impact on overall survival of the presence of selected risk factors: age > 30 years; time from diagnosis to Allo-HSCT > 12 months; presence of an HLA mismatch

	Multivariate analysis		
	HR	**[95%CI]**	**p**
Study population			
0 risk factor (n = 35)	1		
1 risk factor (n = 59)	1.41	[0.53-3.74]	0.488
2 risks factors (n = 41)	3.61	[1.36-9.55]	0.010
3 risks factors (n = 4)	11.90	[2.65-53.35]	0.001
Validation cohort			
0 risk factor (n = 87)	1		
1 risk factor (n = 145)	1.87	[0.988-3.57]	0.055
2 risks factors (n = 55)	2.49	[1.177-5.26]	0.017
3 risks factors (n = 9)	10.19	[3.87-26.89]	<0.001

4-y = 4-year; HR = Hazard ratio; 95%CI = 95% confidence interval

Supplemental Table 3: baseline characteristics of patients in the validation cohort for the SAAWP of EBMT

	Control cohort (N = 296)	
	N	%
Age at Allo-HSCT		
≤ 30 years	233	79%
> 30 years	63	21%
Time from diagnosis to Allo-HSCT (months)		
≤ 12 months	121	41%
> 12 months	175	59%
Unrelated donor		
10/10 MUD	252	85%
9/10 MUD	44	15%
Predictive score		
0-1	232	78%
≥ 2	64	22%
Conditioning		
RIC	176	71%
MAC	71	29%
missing data	49	
Use of TBI	82	28%
missing data	1	
In vivo T-cell depletion	176	85%
missing data	89	
Graft source		
BM	184	62%
PBSC	112	38%

BM = bone marrow; MUD = matched unrelated donor; PBSC = peripheral blood stem cell; TBI = total body irradiation

Supplemental Table 4: Review of major series involving UD Allo-HSCT: number of patients transplanted from a UD; Allo-HSCT period; OS; significant age cut-off for better OS; delay before Allo-HSCT; and impact of HLA matching

Series	N	Allo-HSCT period	OS	Impact of age	Impact of time from diagnosis to Allo-HSCT	Impact of HLA matching
Deeg *et al.*[16]	50	1994-1999	58%	20 years	1 year and 3 years	No
Kojima *et al.*[17]	154	1993-2000	56%	20 years	1 year and 3 years	Yes
Bacigalupo *et al.*[3]	87	1998-2004 2005-2008	68% 83%	13 years	2 years	No
Marsh *et al.*[5]	29	1999-2009	83%	*	*	N/A
Maury *et al.*[4]	37 52	1989-1999 2000-2004	29% 50%	17 years	1 year	Yes
Viollier *et al.*[18]	35 62	1990-1997 1998-2005	32% 57%	*	*	Yes
Devillier *et al.*	46 93	2000-2005 2006-2012	52% 74%	30 years	1 year	Yes

*Age and interval to Allo-HSCT were not specifically assessed for UD Allo-HSCTs.
N/A = Not available